氯吡格雷强化剂量治疗冠脉介入术后氯吡格雷抵抗患者的安全性及有效性比较的Meta分析

摘要/Abstract

摘要： 目的系统评价强化剂量氯吡格雷治疗冠脉介入术后氯吡格雷抵抗患者的有效性和安全性。方法计算机检索PubMed、EMbase、The Cochrane Library、CNKI和WanFang Data,收集有关强化剂量氯吡格雷治疗冠脉介入术后氯吡格雷抵抗患者的随机对照研究,检索时限均为从建库至2016年8月。提取有效数据,评价纳入研究的方法学质量,采用RevMan 5.3 软件进行Meta 分析。结果最终纳入12 个随机对照研究,共计4748例患者,Meta分析结果显示：与常规剂量组相比,强化剂量组再发非致死性心肌梗死（RR=0.59,95% CI[0.39,0.91],P=0.02）、心源性死亡（RR=0.46,95% CI[0.26,0.83],P=0.009）、支架内血栓形成（RR=0.39,95% CI[0.24,0.63],P=0.0001）及复合终点事件（RR=0.48,95% CI[0.36,0.63],P<0.00001）的发生率明显减低,而大出血（RR=0.78,95% CI[0.47,1.31],P=0.35）及小出血事件（RR=1.21,95% CI[0.98,1.51],P=0.08）的发生率方面,两组差异无统计学意义。结论强化剂量氯吡格雷可降低冠脉介入术后氯吡格雷抵抗患者的缺血事件且不增加出血事件的发生。

关键词: 冠状动脉介入术, 氯吡格雷, 氯吡格雷抵抗, Meta分析, 随机对照试验

周美清, 陈小艳, 邓月. 氯吡格雷强化剂量治疗冠脉介入术后氯吡格雷抵抗患者的安全性及有效性比较的Meta分析[J]. 心血管病防治知识, 2021, 11(15): 19-25.

参考文献

[1] Wiviott SD, Braunwald E, McCabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Eng J Med ,2007,357:2001-2015.
[2] Stone GW, Witzenbichler B, Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study[J]. Lancet,2013,382:614-623.
[3] Sibbing D, Braun S, Jawansky S, et al.Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment[J]. Thromb Haemost,2008,99: 121-126.
[4] Bonello L,Camoin-Jau L,Arques S,et al.Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a muhicenter randomized prospective study[J].J Am Coil Cardiol,2008,5 1:1404-1411.
[5] von Beckerath N, Taubert D, Pogatsa-Murray G,et al.Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J].Circulation,2005 ,112(19):2946-2950.
[6] Montalescot G, Sideris G, Meuleman C,et al.A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial[J].J Am Coll Cardiol,2006,48(5):931-938.
[7] Patti G, Colonna G, Pasceri V, et al.Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty) study[J]. Circulation,2005;111:2099-2106.
[8] Montalescot G, Sideris G, Meuleman C, et al.A randomized comparison of high clopidogrel loading doses in patients with non-ST-elevation acute coronary syndromes: the ALBION trial[J]. J Am Coll Cardiol,2006,48:931-938.
[9] Ari H, Ozkan H, Karacinar A, et al. The EFFect of high-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial)[J]. Int J Cardiol,2011,Epub ahead of print.
[10] Bonello L, Camoin-Jau L, Armero S, et al.Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis[J].Am J Cardiol,2009,103:5-10.
[11] Price MJ, Berger PB, Teirstein PS, et al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J]. JAMA, 2011,305:1097-1105.
[12] Higgins JP, Green S.Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0]. [cited 2012 Jan 5]. Available at: http://www.cochrane-handbook.org.
[13] Wang XD, Zhang DF, Zhuang SW,et al.Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance[J].Clin Cardiol, 2011,34(5):332-338.
[14] Aradi D, Rideg O, Vorobcsuk A,et al.Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity[J].Eur J Clin Invest,2012,42(4):384-392.
[15] Guan SY, Han YL, Li Y,et al.Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation[J].Zhonghua Xin Xue Guan Bing Za Zhi,2012 ,40(1):25-29.
[16] Gremmel T, Steiner S, Seidinger D,et al.A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity[J].Int J Cardiol, 2012 ,160(2):109-113.
[17] Tang FK, Lin LJ, Hua N,et al.Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention[J].Chin Med J (Engl),2012 ,125(4):631-638.
[18] Samardzic J, Krpan M, Skoric B,et al.Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity[J].J Thromb Thrombolysis,2014,38(4):459-469.
[19] Liang J, Wang Z, Shi D, et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention[J].Angiology.2015 Apr;66(4):319-325.
[20] 路靖. 高维持剂量氯吡格雷对冠脉介入治疗的急性冠脉综合征患者围手术期血小板活性的影响[D].石家庄:河北医科大学,2012.
[21] TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2007,357(20):2001-2015.
[22] Wallentin L, Becker RC, Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J, 2009 ,361(11):1045-1057.
[23] 齐新,刘克强,王敏,等.冠心病患者血小板聚集功能与炎症因子关系的研究[J].中国循环杂志,2009, 24(3):178-181.
[24] Sibbing D, Steinhubl SR, Schulz S,et al.Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients:Initial evidence of a therapeutic window[J]. J Am Coll Cardio,2010,56:317-318.
[25] Price MJ, Angiolillo DJ, Teirstein PS, et al.Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention:A time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay:Impact on thrombosis and safety (GRAVITAS) trial[J].Circulation,2011,124:1132-1137.
[26] Xu ZH, Jiao JR, Yang R,et al.Aspirin resistance: clinical significance and genetic polymorphism[J].J Int Med Res, 2012,40(1):282-292.
[27] Bonello L, Tantry US, Marcucci R,et al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J].J Am Coll Cardiol,2010,56(12):919-933.
[28] Cuisset T, Frere C, Quilici J,et al.High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome[J].J Thromb Haemost,2006,4(3):542-549.
[29] Breet NJ, van Werkum JW, Bouman HJ,et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J].JAMA,2010 ,303(8):754-62.
[30] Hamm CW, Bassand JP, Agewall S, et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2011,32(23):2999-3054.
[31] Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI guideline for percutaneous.